ArticlePloS one2017
Effect of hyperbaric oxygen on BDNF-release and neuroprotection: Investigations with human mesenchymal stem cells and genetically modified NIH3T3 fibroblasts as putative cell therapeutics.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Effectiveness and safety of hyperbaric oxygen therapy for psychiatric disorders: A systematic review and meta-analysis.Psychiatry and clinical neurosciences · 2026Pooled it
- Method for AFM investigation of lateral forces required for the surface detachment of neurites.Scientific reports · 2026Article
- Complex Hippocampal Response to Thermal Skin Injury and Protocols with Hyperbaric Oxygen Therapy andInternational journal of molecular sciences · 2024Article
- Hyperbaric oxygen therapy as a neuromodulatory technique: a review of the recent evidence.Frontiers in neurology · 2024Review
- Hyperbaric oxygen therapy for healthy aging: From mechanisms to therapeutics.Redox biology · 2022Review
- PLLA Coating of Active Implants for Dual Drug Release.Molecules (Basel, Switzerland) · 2022Article
- Hyperoxygenation Ameliorates Stress-induced Neuronal and Behavioral Deficits.Experimental neurobiology · 2021Article
- Hyperbaric Oxygen Treatment: Effects on Mitochondrial Function and Oxidative Stress.Biomolecules · 2021Review
- The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.Advances in experimental medicine and biology · 2021Review
- Extracellular vesicles from human multipotent stromal cells protect against hearing loss after noise trauma in vivo.Clinical and translational medicine · 2020Article
- Review
- BDNF-overexpressing human mesenchymal stem cells mediate increased neuronal protection in vitro.Journal of neuroscience research · 2019Article
- Effect of Hyperbaric Oxygen on Proliferation and Gene Expression of Human Chondrocytes: AnCartilage · 2019Article
- Engraftment of Human Stem Cell-Derived Otic Progenitors in the Damaged Cochlea.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Early Hyperbaric Oxygen Treatment Attenuates Burn-Induced Neuroinflammation by Inhibiting the Galectin-3-Dependent Toll-Like Receptor-4 Pathway in a Rat Model.International journal of molecular sciences · 2018Article
- A Dual Role for Hyperbaric Oxygen in Stroke Neuroprotection: Preconditioning of the Brain and Stem Cells.Conditioning medicine · 2018Article
- A review on the neuroprotective effects of hyperbaric oxygen therapy.Medical gas researchReview
- Alginate-encapsulated brain-derived neurotrophic factor-overexpressing mesenchymal stem cells are a promising drug delivery system for protection of auditory neurons.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperbaric oxygen therapy (HBOT) is a noninvasive widely applied treatment that increases the oxygen pressure in tissues. In cochlear implant (CI) research, intracochlear application of neurotrophic factors (NTFs) is able to improve survival of spiral ganglion neurons (SGN) after deafness. Cell-based delivery of NTFs such as brain-derived neurotrophic factor (BDNF) may be realized by cell-coating of the surface of the CI electrode. Human mesenchymal stem cells (MSC) secrete a variety of different neurotrophic factors and may be used for the development of a biohybrid electrode in order to release endogenously-derived neuroprotective factors for the protection of residual SGN and for a guided outgrowth of dendrites in the direction of the CI electrode. HBOT could be used to influence cell behaviour after transplantation to the inner ear. The aim of this study was to investigate the effect of HBOT on the proliferation, BDNF-release and secretion of neuroprotective factors. Thus, model cells (an immortalized fibroblast cell line (NIH3T3)-native and genetically modified) and MSCs were repeatedly (3 x - 10 x) exposed to 100% oxygen at different pressures. The effects of HBO on cell proliferation were investigated in relation to normoxic and normobaric conditions (NOR). Moreover, the neuroprotective and neuroregenerative effects of HBO-treated cells were analysed by cultivation of SGN in conditioned medium. Both, the genetically modified NIH3T3/BDNF and native NIH3T3 fibroblasts, showed a highly significant increased proliferation after five days of HBOT in comparison to normoxic controls. By contrast, the number of MSCs was decreased in MSCs treated with 2.0 bar of HBO. Treating SGN cultures with supernatants of fibroblasts and MSCs significantly increased the survival rate of SGN. HBO treatment did not influence (increase / reduce) this effect. Secretome analysis showed that HBO treatment altered the protein expression pattern in MSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.